Literature DB >> 12181489

Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.

Koichi Kokame1, Masanori Matsumoto, Kenji Soejima, Hideo Yagi, Hiromichi Ishizashi, Masahisa Funato, Hiroshi Tamai, Mutsuko Konno, Kei Kamide, Yuhei Kawano, Toshiyuki Miyata, Yoshihiro Fujimura.   

Abstract

von Willebrand factor (VWF) is synthesized primarily in vascular endothelial cells and secreted into the plasma as unusually large VWF multimers. Normally, these multimers are quickly degraded into smaller forms by a plasma metalloproteinase, VWF-cleaving protease (VWF-CP). Decreases in the activity of this enzyme result in congenital and acquired thrombotic thrombocytopenic purpura (TTP). The human VWF-CP has recently been purified. Cloning of the corresponding cDNA revealed that the 1,427-aa polypeptide is a member of the ADAMTS gene family, termed ADAMTS13. Twelve rare mutations in this gene have been identified in patients with congenital TTP. Here, we report missense and nonsense mutations in two Japanese families with Upshaw-Schulman syndrome, congenital TTP with neonatal onset and frequent relapses. The comparison of individual ADAMTS13 genotypes and plasma VWF-CP activities indicated that the R268P, Q449stop, and C508Y mutations abrogated activity of the enzyme, whereas the P475S mutant retained low but significant activity. The effects of these mutations were further confirmed by expression analysis in HeLa cells. Recombinant VWF-CP containing either the R268P or C508Y mutations was not secreted from cells. In contrast, Q449stop and P475S mutants were normally secreted but demonstrated minimal activity. Genotype analysis of 364 Japanese subjects revealed that P475S is heterozygous in 9.6% of individuals, suggesting that approximately 10% of the Japanese population possesses reduced VWF-CP activity. We report on a single-nucleotide polymorphism associated with alterations in VWF-CP activity; it will be important to assess this single-nucleotide polymorphism as a risk factor for thrombotic disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181489      PMCID: PMC129366          DOI: 10.1073/pnas.172277399

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Thrombotic thrombocytopenic purpura: a paradigm shift?

Authors:  D B Cines; B A Konkle; M Furlan
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

Review 2.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

Authors:  M Furlan; B Lämmle
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.

Authors:  Y Sugio; T Okamura; K Shimoda; M Matsumoto; H Yagi; H Ishizashi; Y Niho; S Inaba; Y Fujimura
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

5.  A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?

Authors:  K Soejima; N Mimura; M Hirashima; H Maeda; T Hamamoto; T Nakagaki; C Nozaki
Journal:  J Biochem       Date:  2001-10       Impact factor: 3.387

6.  Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.

Authors:  S Kinoshita; A Yoshioka; Y D Park; H Ishizashi; M Konno; M Funato; T Matsui; K Titani; H Yagi; M Matsumoto; Y Fujimura
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

7.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

Authors:  K Fujikawa; H Suzuki; B McMullen; D Chung
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

9.  Clopidogrel and side effects.

Authors:  F Reichenberger; H Wirtz; R Paschke
Journal:  Cardiology       Date:  2001       Impact factor: 1.869

Review 10.  Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  P J Medina; J M Sipols; J N George
Journal:  Curr Opin Hematol       Date:  2001-09       Impact factor: 3.284

View more
  78 in total

1.  A new name in thrombosis, ADAMTS13.

Authors:  J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

3.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

Review 4.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

Review 5.  Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation.

Authors:  Toshiyuki Miyata; Rina Kimura; Yoshihiro Kokubo; Toshiyuki Sakata
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 6.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

7.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

Review 8.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

9.  Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Journal:  J Mol Model       Date:  2004-08-03       Impact factor: 1.810

Review 10.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.